

# A Study to Assess the Safety and Effects of the Investigational Drug BW-40202 in Healthy Volunteers

NCT06917482

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Shanghai Argo Biopharmaceutical Co., Ltd.
Enrollment	40 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Must have given written informed consent and be able to comply with all study requirements.
- Males or females aged 18 to 60 years old, inclusive, at the time of informed consent.
- BMI  $\geq 18$  and  $\leq 32$  kg/m<sup>2</sup> with 50 kg  $\leq$  body weight  $\leq 100$  kg.

### Exclusion (10)

- Any clinically significant chronic medical condition or clinically significant abnormality in laboratory parameters that, in the opinion of the investigator, makes the subject unsuitable for participation in the study.
- Hospitalization for any reason within 60 days prior to screening.
- Any clinically significant acute condition such as fever ( $\geq 38$  degree centigrade) or acute respiratory illness within 14 days of study drug administration.
- Systolic blood pressure (more than equal to) 140 mmHg and/or diastolic blood pressure (more than equal to) 90 mmHg after at least 5 minutes resting (seated or supine) at screening and Day -1 (Repeat blood pressure measurement will be allowed at the discretion of the investigator).
- Any liver function panel analyte value  $> 1.2 \times$  upper limits of normal (ULN) which includes aspartate transaminase (AST), alanine transaminase (ALT), total bilirubin (TBIL), alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) at screening.
- ... and 5 more (see full listing online)

## Locations (2 total)

---

Q-Pharm Pty Ltd., Brisbane, Queensland, Australia  
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia